Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca To Launch Phase I Trial Of Liver Cancer Drug Developed In China

This article was originally published in PharmAsia News

Executive Summary

An AstraZeneca drug said to be the first of its kind to be developed in China by a multinational drug maker is about to undergo clinical trials to see if it is effective for treating liver cancer. The disease is China's second-largest killer, lung cancer being first. China's State FDA has approved the Phase I clinical trial, a step somewhat unusual since China often relies on results from a first-stage abroad before approving one locally. The drug was developed through global chemistry research by the company's Chinese innovation center, its sole research facility in Asia. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts